ArticleTheScientificWorldJournal2022
Acute and Subacute Toxicity Assessment of Andrographolide-2-hydroxypropyl-
Article in TheScientificWorldJournal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Evaluating Safety and Efficacy of Bio-Immune (Andrographolide) in Managing URTI Symptoms: A Randomized, Double-Blinded, Placebo-Controlled, Single-Center, Comparative Study.TheScientificWorldJournal · 2026Trial
- Andrographolide in Sepsis: Mechanistic Basis, New Drug States, and Advanced Delivery Systems.International journal of general medicine · 2026Review
- Article
- Anti-Cancer Agent: The Labdane Diterpenoid-Andrographolide.Plants (Basel, Switzerland) · 2023Review
- Antiviral Mechanism of Virucidal Sialic Acid Modified Cyclodextrin.Pharmaceutics · 2023Article
- Endocytosis inhibitors block SARS-CoV-2 pseudoparticle infection of mink lung epithelium.Frontiers in microbiology · 2023Article
- Andrographolide, a natural anti-inflammatory agent: An Update.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute and subacute toxicity analysis of AND-2-HyP- Methods and Results: Single dose acute toxicity was carried out at 2000 mg/kg of AND-2-HyP- Conclusion: The findings of the present study would further be useful in assessing and utilizing the medicinal and therapeutic benefits of AND-2-HyP-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.